Michael Schweizer, MD
Enriched profileProfessor, Division of Hematology and Oncology · University of Washington
Michael Schweizer is Professor, Division of Hematology and Oncology at University of Washington. OpenAlex indexes 290 publications with 7,258 citations (h-index 43); ClinicalTrials.gov lists 21 registered studies with this person as an investigator.
Data verified 7 Nov 2026
Overview
Updated 7 Nov 2026
Michael Schweizer, M.D., is Professor, Division of Hematology and Oncology at University of Washington. The public record shows 290 publications with 7,258 citations (h-index 43), centered on Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Cancer Genomics and Diagnostics. It also documents an investigator role on 21 registered clinical trials, industry payments reported by 5 companies, 1 NIH-funded awards (2024–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Prostate Cancer Treatment and Research
- 21 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 7 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. 31 in PubMed. Counts exclude supporting files.
Citations across these publications.
H-index from these publications. i10-index 105.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 7 Nov 2026
Listed as an investigator on 21 registered studies on ClinicalTrials.gov. The most recent:
- Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer
Sponsor: ECOG-ACRIN Cancer Research Group
- A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy
Sponsor: Prostate Cancer Clinical Trials Consortium
Industry payments
Updated 7 Nov 2026
5 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20252 payments
- PFIZER INC.Program year20251 payment
- PFIZER INC.Program year20242 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
45.1%Corticosteroid38.4%Prednisone100%Part D≥31 patientsSerotonin-3 Receptor Antagonist6.7%Ondansetron Hcl100%Part D≥15 patientsCancer & immunology
43%Cytochrome P450 17A1 Inhibitor31.3%Abiraterone Acetate100%Part D≥23 patientsAnti-androgens6.7%Nubeqa100%Part D<11 patients+ 1 more class in this area
Sensory organs
6.7%Corticosteroid6.7%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 7 Nov 2026
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy
Fred Hutchinson Cancer Center
FY2026$667,980R37CA286450 - Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy
Fred Hutchinson Cancer Center
FY2025$668,068R37CA286450 - Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy
Fred Hutchinson Cancer Center
FY2024$720,165R37CA286450
Congress activity
Updated 7 Nov 2026
107 congress contributions (2010–2026) across AACR, ASCO, ASTRO, AUA, ESMO per OpenAlex. The most recent:
- Abstract LB006: Prostate cancer phenotypes determined from circulating tumor DNA associate with outcomes to 177Lu-PSMA-617 therapy
AACR Annual Meeting
AACR2026Co-authorLate-breaking
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 7 Nov 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- SPEN Inactivation Drives Resistance to Androgen Receptor Pathway Inhibitors in Metastatic Prostate Cancer.
Clinical cancer research
Article2026 - Image-based Detection of Mismatch Repair Deficiency in Prostate Cancer Using Transfer Learning.
Clinical cancer research
Article2026 - Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer.
Prostate cancer and prostatic diseases
Article2026 - Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.
Molecular cancer research
Article2026
Online presence
Updated 7 Nov 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/michael-schweizer-md
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/michael-schweizer-475a64272
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Michael-Schweizer-3
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Apple Podcasts
podcasts.apple.com/us/podcast/high-dose-testosterone-bat-for-prostate-cancer-with-dr/id1609860250
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - Other
hemonc.uw.edu/people/michael-schweizer
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hemonc.uw.edu ↗ - Other
urotoday.com/video-lectures/asco-2024/video-2/4130-targeting-ezh2-in-prostate-cancer-the-role-of-mevrometostat-in-preventing-neuroendocrine-differentiation-michael-schweizer.html
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urotoday.com ↗ - Spotify
open.spotify.com/episode/3MvOzH3mAcUB3lsYelzdKn
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →open.spotify.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 7 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Temple University School of Medicine
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hemonc.uw.edu ↗ - Medical Oncology
American Board of Internal Medicine
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hemonc.uw.edu ↗ - Internal Medicine
American Board of Internal Medicine
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hemonc.uw.edu ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →fredhutch.org ↗
- Clinical Research Director
GU/Prostate, Fred Hutch and UW Medicine
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hemonc.uw.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hemonc.uw.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urotoday.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →open.spotify.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Rainer Storb
University of Washington
Connie Celum, MD, MPH
University of Washington
Helen Chu, MD, MPH
University of Washington
Bryan Kestenbaum, MD
University of Washington
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)